Combining the aromatase inhibitor, letrozole, with a RET inhibitor has demonstrated improved efficacy over letrozole alone in preclinical models13 and clinical trials are evaluating the use of RET inhibitors to enhance sensitivity and reduce resistance to hormonal therapies in breast cancers (clinicaltrials.gov). Here, RET is linked to breast carcinoma.